$20.59
2.79% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$20.59
-2.59 11.17% 1M
-9.63 31.87% 6M
-11.25 35.33% YTD
-11.12 35.07% 1Y
-20.58 49.99% 3Y
-1.75 7.83% 5Y
+16.03 351.63% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.59 2.79%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $13.08b
Enterprise Value $10.63b
P/E (TTM) P/E ratio 19.69
EV/FCF (TTM) EV/FCF 11.28
EV/Sales (TTM) EV/Sales 3.70
P/S ratio (TTM) P/S ratio 4.55
P/B ratio (TTM) P/B ratio 2.74
Revenue growth (TTM) Revenue growth 18.04%
Revenue (TTM) Revenue $2.87b
EBIT (operating result TTM) EBIT $931.50m
Free Cash Flow (TTM) Free Cash Flow $942.23m
Cash position $2.59b
EPS (TTM) EPS $1.05
P/E forward 16.94
P/S forward 4.38
EV/Sales forward 3.58
Short interest 0.37%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

17x Buy
63%
9x Hold
33%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

Buy
63%
Hold
33%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,873 2,873
18% 18%
100%
- Direct Costs 113 113
-
4%
2,760 2,760
-
96%
- Selling and Administrative Expenses 516 516
10% 10%
18%
- Research and Development Expense 1,313 1,313
25% 25%
46%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 932 932
4% 4%
32%
Net Profit 675 675
9% 9%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
Seeking Alpha
6 days ago
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Jonathan Chang - LeeRink Partners Paul Jeng - Guggenheim Securities, LLC Zain Ebrahim - JP...
Neutral
GlobeNewsWire
9 days ago
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy Genmab announced that it will assu...
Positive
Seeking Alpha
10 days ago
Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Gen...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,204
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today